Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA
目录号 : GC34141
Cyclo(Arg-Gly-Asp-D-Phe-Val)(TFA)是整合蛋白αvβ3的抑制剂,具有抗肿瘤活性。
Cas No.:199807-33-5
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: |
The osteoblasts are cultured in RPMI 1640 medium for 2 days. MV4-11 cells (1.8×105 cells/mL in the 2D culture system and 1×106 cells/mL in the 3D culture system) are co-cultured with leukemia osteoblasts in RPMI 1640 medium. The experiments used two groups: The experimental group received c(RGDfV) (35 nmol/mL) and the control group received an equal volume of phosphate-buffered saline (PBS) only[1]. |
References: [1]. Shen ZH, et al. Targeting of the leukemia microenvironment by c(RGDfV) overcomes the resistance to chemotherapy in acute myeloid leukemia in biomimetic polystyrene scaffolds. Oncol Lett. 2016 Nov;12(5):3278-3284. |
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an inhibitor of integrin αvβ3, with antitumor activity.
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an inhibitor of integrin αvβ3. Cyclo(Arg-Gly-Asp-D-Phe-Val) [c(RGDfV); 35 nM] induces disruption of leukemia cell migration and adhesion to leukemia osteoblasts in the 3D and 2D culture systems, affects the leukemia cell cycle and induces apoptosis in leukemia cells[1].
[1]. Shen ZH, et al. Targeting of the leukemia microenvironment by c(RGDfV) overcomes the resistance to chemotherapy in acute myeloid leukemia in biomimetic polystyrene scaffolds. Oncol Lett. 2016 Nov;12(5):3278-3284.
Cas No. | 199807-33-5 | SDF | |
Canonical SMILES | Cyclo(Arg-Gly-Asp-{d-Phe}-Val) | ||
分子式 | C28H39F3N8O9 | 分子量 | 688.65 |
溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 1.4521 mL | 7.2606 mL | 14.5212 mL |
5 mM | 0.2904 mL | 1.4521 mL | 2.9042 mL |
10 mM | 0.1452 mL | 0.7261 mL | 1.4521 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。